Donations

What are Donations?  

Donations, like grants, are funds, benefits-in-kind, or services freely given for the purpose of supporting healthcare, scientific research or education, with no consequent obligation on the recipient organisation, institution and the like to provide goods or services to the benefit of the pharmaceutical company in return.  

Donations and grants to individuals are prohibited. In general, donations are physical items, services or benefits-in-kind which may be offered or requested. Grants are the provision of funds. 

 

Disclosure and compliance  

As a UK-based pharmaceutical company, Daiichi Sankyo UK adheres to the ABPI Code of Practice, including the requirements for annual disclosure of transfer of value for the corresponding period.  

Details of each donation or grant (transfer of value) must be publicly disclosed annually, giving in each case the financial amount or value and the name of the recipient institution, organisation, or association. Companies are also encouraged to ask recipients to make such funding public. Where applicable, fees and expenses should be disclosed separately. Disclosure must be carried out in accordance with Clauses 28 and 29. 

Further information on Donations as defined under the ABPI code can be found via Clause 23 of the ABPI Code of Practice.  

 

Donations for NHS organisations under the terms of the NHS England and NHS Improvement Framework Agreement 

Daiichi Sankyo (DSUK) have committed to provide ongoing funding towards approved Detect, Protect and Perfect ‘DPP’ initiatives under the terms of the National Framework Agreement with NHS England and NHS Improvement (NHSEI). The purpose of these initiatives is to:

  • Reduce the number of undiagnosed patients; and/or 
  • Reduce the number of patients not anticoagulated; and/or
  • Improve patient management and / or adherence and/or
  • Improve patient safety 

All inititaives are product-agnostic, non-promotional and do not constitute an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific medicines.  
 

Donation-based services available to support Detect, Protect, Perfect objectives 

The following arrangements have been agreed between NHSEI and DSUK in the delivery of these services. Donations from DSUK, as defined in the ABPI code, will now be available for the following services.  

1. Therapy Optimisation Programme (‘Therapy Reviews’) 

The service is a clinical therapy review service to assist practices in the implementation of a systematic approach to the therapeutic management Atrial Fibrillation (AF) in relation to stroke prevention and is aligned to support national clinical strategies.  

The purpose of therapy reviews is to identify patients that either have a diagnosis of AF and are not receiving an anticoagulant or whose therapy may be in need of adjustment, based on a set of clinical criteria agreed with the lead physician of the GP practice. 

The service is delivered by either of DSUK’s existing therapy review third-party providers, including Inspira Health and Medicines Management Solutions (MMS). 

2. AF Quality Improvement (AFQI) Dashboard  

The aim of this initiative is to support practices in identifying opportunities to improve the effective anticoagulation of their AF patients through providing a clinical review platform, education, and an implementation plan to optimise patient care. The service enables local healthcare systems to identify Protect and Perfect gaps in order to reduce the risk of stroke due to atrial fibrillation (AF).   

It is designed to support clinicians by providing them with the tools and resources required to identify those at risk of stroke from AF and make their own clinical decisions to improve the effective anticoagulation of the AF population. 

Delivered by Interface Clinical Services, this is aimed at supporting commissioners and healthcare professionals which request AF support but with a preference to implement change using their in-house clinical teams.   

Requests for either AF Quality Improvement Dashboard or Therapy Optimisation programmes outlined above will be considered on an ongoing basis until end of March 2023. Further initiatives will be made available, and communicated, later in 2022.

Application criteria 

Under the terms of the National Framework Agreement, DSUK and NHSEI have agreed the following application criteria. Applications will be approved, based on available budget and that the cost is comparable with other similar schemes, for requests that meet the following criteria:
1.    The service includes practices with a registered QOF population of not less than 30,000; and
2.    The population when ranked by the number of:
    a)    Diagnosed but untreated patients (QOF AF Registry – number of patients anticoagulated); or 
    b)    Estimated undiagnosed patients (PHE estimate – QOF AF Registry); 
is in the top 2 national quartiles. Details relating to the quartiles is managed by DSUK and NHSEI and is based on a combination of QOF and PHE data.

3.    That the scheme is supported by the responsible commissioning authority (CCG/ICS). e.g. PCNs need to inform their CCG / ICS of their request for funding.


Applications which meet the above will be funded by DSUK. Applications that do not satisfy the above may be funded subject to further discussion between, and if supported by, both DSUK and NHSEI. The population criteria included to encourage ‘at-scale’ schemes and to prioritise areas with the highest undetected and untreated populations.
 

 

 

For further information 

To apply for a service, please download this service request form. 

For therapy review applications please send the service request form to therapyreviews@daiichi-sankyo.co.uk  

For the AF Quality Improvement Dashboard service, please send the form to DPP@daiichi-sankyo.co.uk  

For further information regarding Daiichi Sankyo’s ongoing support for DPP initiatives, please contact DPP@daiichi-sankyo.co.uk  

 

DSC/22/0097 May 2022

back to top